Chronic Refractory Cough Drug Pipeline Analysis Report 2025

Chronic refractory cough is a persistent cough lasting over eight weeks despite treatment, significantly impacting patients' quality of life. It accounts for approximately 2%-18% of chronic cough cases worldwide. With a growing demand for advanced therapies, pharmaceutical companies are increasingly focusing on chronic refractory cough drug candidates. Recent advancements include neuromodulators, P2X3 purinoceptor antagonists, and novel anti-inflammatory agents. The pipeline for these treatments is expected to expand as clinical trials advance, regulatory approvals increase, and awareness of the condition improves.

Report Coverage

The Chronic Refractory Cough Drug Pipeline Insight Report by the publisher gives comprehensive insights into chronic refractory cough therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for chronic refractory cough. The chronic refractory cough report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The chronic refractory cough pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with chronic refractory cough treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to chronic refractory cough.

Chronic Refractory Cough Drug Pipeline Outlook

Chronic refractory cough is a persistent cough lasting over eight weeks that does not respond to standard treatments. It often results from heightened nerve sensitivity in the airways, triggered by infections, allergies, or acid reflux. It can significantly impact daily life, causing discomfort, sleep disturbances, and social embarrassment.

Chronic refractory cough treatments focus on symptom relief. Options include neuromodulators like gabapentin, speech therapy, and cough suppression techniques. Emerging therapies, such as P2X3 receptor antagonists, target nerve hypersensitivity. Lifestyle modifications, including hydration and avoiding irritants, can help manage symptoms effectively.

Chronic Refractory Cough Epidemiology

The global prevalence of chronic cough is estimated to be between 2% and 18%. A cough lasting more than eight weeks is classified as chronic and affects approximately 10% of adults in the United States. Web-based National Health and Wellness Surveys report a 12-month prevalence of around 5% in Japan, Germany, the United States, and Spain. In Spain, the estimated lifetime prevalence is 8.2%, impacting 3.3 million adults.

Chronic Refractory Cough - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of chronic refractory cough drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Monoclonal Antibodies
• RNA-based Therapies
• Peptide Antagonists
• Combination Therapies

By Route of Administration

• Oral
• Parenteral
• Others

Chronic Refractory Cough - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total chronic refractory cough clinical trials.

Chronic Refractory Cough - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the chronic refractory cough pipeline analysis include small molecules, monoclonal antibodies, RNA-based therapies, peptide antagonists, and combination therapies. The chronic refractory cough report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for chronic refractory cough.

Chronic Refractory Cough Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the chronic refractory cough drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed chronic refractory cough therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in chronic refractory cough clinical trials:

• Trevi Therapeutics
• Bellus Health Inc.
• Nocion Therapeutics
• Melius Pharma AB
• Jiangsu Hansoh Pharmaceutical Co., Ltd.
• Merck Sharp & Dohme LLC
• Beijing Tide Pharmaceutical Co., Ltd.
• Vyne Therapeutics Inc.

Chronic Refractory Cough Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for chronic refractory cough. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of chronic refractory cough drug candidates.

Drug: BLU-5937

BLU-5937, currently being investigated in a Phase III study sponsored by Bellus Health Inc. (a GSK company), targets refractory chronic cough. It works by inhibiting P2X3 receptors on sensory neurons to reduce cough reflex hypersensitivity. The study aims to assess its efficacy in reducing 24-hour cough frequency.

Drug: Nalbuphine ER

Nalbuphine ER (NAL ER), developed by Trevi Therapeutics, is being evaluated for the treatment of refractory chronic cough (RCC). It modulates the cough reflex arc through its dual mechanism as a kappa agonist and mu antagonist (KAMA). The objective of this Phase II study is to assess its efficacy and safety in RCC patients.

Drug: NOC-110

NOC-110 is undergoing Phase II clinical development for refractory or unexplained chronic cough. The clinical trial, conducted by Nocion Therapeutics, aims to evaluate its efficacy, safety, and tolerability. NOC-110, an inhalation powder, works by silencing activated nociceptors through sodium channel blockade, potentially offering superior antitussive effects compared to P2X3 antagonists.

Reasons To Buy This Report

The Chronic Refractory Cough Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for chronic refractory cough. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into chronic refractory cough collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Chronic Refractory Cough - Pipeline Insight Report

• Which companies/institutions are leading the chronic refractory cough drug development?
• What is the efficacy and safety profile of chronic refractory cough pipeline drugs?
• Which company is leading the chronic refractory cough pipeline development activities?
• What is the current chronic refractory cough commercial assessment?
• What are the opportunities and challenges present in the chronic refractory cough drug pipeline landscape?
• What is the efficacy and safety profile of chronic refractory cough pipeline drugs?
• Which company is conducting major trials for chronic refractory cough drugs?
• Which companies/institutions are involved in chronic refractory cough collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in chronic refractory cough?

This product will be delivered within 3-5 business days.